Partners Nuclera Nuclera has committed to working toward the sustainable development goals (sdgs) that both align with our business model and relevant to our industry. By partnering with leadxpro, we can pair ai ml driven construct design with our rapid multiplex membrane protein screening to provide a truly ‘lab in loop’ workflow.
Making Proteins Accessible Nuclera Nuclera, the biotechnology company enabling rapid access to high quality proteins and leadxpro, a specialist in structure based drug discovery for membrane proteins, today announced a scientific partnership. Exciting news: nuclera partners with sharp life science (eu) limited to advance it's digital microfluidics capabilities 🚀 we're thrilled to announce our exclusive partnership with sharp life. The partnership with sls eu will help nuclera develop future generations of the eprotein discoverytm system to provide ever more advanced features to drug discovery researchers. Nuclera, the biotechnology company enabling rapid access to high quality proteins and leadxpro, a specialist in structure based drug discovery for membrane proteins, today announced a scientific partnership.
About Us Nuclera The partnership with sls eu will help nuclera develop future generations of the eprotein discoverytm system to provide ever more advanced features to drug discovery researchers. Nuclera, the biotechnology company enabling rapid access to high quality proteins and leadxpro, a specialist in structure based drug discovery for membrane proteins, today announced a scientific partnership. Nuclera, the biotechnology company enabling rapid access to high quality proteins and leadxpro, a specialist in structure based drug discovery for membrane proteins, today announced a scientific. Nuclera operates the world’s most advanced digital microfluidic system for biotechnology applications. overall, the work with sls eu will enable nuclera to further increase its ip moat around “high resolution” active matrix thin film transistor based digital microfluidics. At nuclera, we understand that every scientist needs rapid access to high quality, novel proteins. multiplex protein screening draws a straight line from theory to reality, allowing scientists to know which proteins have the best change of success from the start. At nuclera, we are excited to announce that we have established a distribution network across the asia pacific (apac) region and the middle east.
About Us Nuclera Nuclera, the biotechnology company enabling rapid access to high quality proteins and leadxpro, a specialist in structure based drug discovery for membrane proteins, today announced a scientific. Nuclera operates the world’s most advanced digital microfluidic system for biotechnology applications. overall, the work with sls eu will enable nuclera to further increase its ip moat around “high resolution” active matrix thin film transistor based digital microfluidics. At nuclera, we understand that every scientist needs rapid access to high quality, novel proteins. multiplex protein screening draws a straight line from theory to reality, allowing scientists to know which proteins have the best change of success from the start. At nuclera, we are excited to announce that we have established a distribution network across the asia pacific (apac) region and the middle east.
Protein Expression System Nuclera At nuclera, we understand that every scientist needs rapid access to high quality, novel proteins. multiplex protein screening draws a straight line from theory to reality, allowing scientists to know which proteins have the best change of success from the start. At nuclera, we are excited to announce that we have established a distribution network across the asia pacific (apac) region and the middle east.
Comments are closed.